BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25816709)

  • 1. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
    Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
    Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
    Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
    Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R
    Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
    Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
    Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
    Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
    Krejci M; Scudla V; Tothova E; Schutzova M; Koza V; Adam Z; Krivanova A; Pour L; Buchler T; Sandecka V; Kralova D; Zahradova L; Vorlicek J; Mayer J; Hajek R
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):436-42. PubMed ID: 19951883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
    Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
    Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
    Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.
    Barley K; Tindle S; Bagiella E; Jagannath S; Chari A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):541-5. PubMed ID: 26119495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients.
    Scudla V; Bacovsky J; Indrak K; Kodouskova V; Vytrasova M; Faber E; Papajik T; Adam Z; Hajek R; Horak P; Martinek A;
    Hematol J; 2003; 4(5):351-7. PubMed ID: 14502261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.